Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions The treatment of nivolumab offers durable responses, 31.1% demonstrated partial responses with an acceptable safety profile at high costs. However, the immature OS data in combination with the lack of evidence for the actual patient population affected most by CRC in clinical practice highlight the requirement for long-term data. Moreover, head-to-head comparisons will be necessary to identify the best treatment option for CRC patients with dMMR/MSI-H. Ultimately, trustworthy biomarker testing will be needed to select those patients who benefit most from nivolumab. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Colonic Neoplasms; Colorectal Neoplasms; DNA Mismatch Repair; Diagnostic Tests, Routine; Humans; Microsatellite Instability; nivolumab Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32018000198 Date abstract record published 16/04/2018 |